Skip to main content
Signal8

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

$VNRXPress releaseMay 14, 2026, 4:10 PM ETRead the release

VolitionRx reported Q1 2026 revenue of $1.0 million, a 400% increase year-over-year from $0.2 million, driven by early commercial activity and licensing discussions. The company raised approximately $7.3 million in total capital during the quarter, including $5.4 million from at-the-market equity sales, $1.9 million from a convertible note, and $1.0 million in non-dilutive grants from the Walloon Region.

Key figures

Revenue
1000000
Revenue Yoy
400%
Atm equity proceeds
5400000
Operating loss change
-3%
Grant funding expected
900000
Grant funding received
1000000
Net cash used operating
5300000
Convertible note proceeds
1900000
Potential milestone payment
5000000

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.